Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / FRLN - Freeline Therapeutics spikes as Syncona discloses stake

FRLN - Freeline Therapeutics spikes as Syncona discloses stake

Freeline Therapeutics Holdings plc
Freeline Therapeutics (NASDAQ:FRLN) has added ~17% in the post-market Friday on the news that Guernsey-based investment firm Syncona Limited has a ~63% stake in the clinical-stage biotechnology company. Syncona has revealed the position through a 13-D filing submitted to the Securities and Exchange Commission last week. Syncona operates as a closed-ended investment company focused on life science businesses. Freeline Therapeutics (FRLN) has lost more than 90% over the past twelve months underperforming the broader market, as shown in this graph. The company shares surged early this month in reaction to regulatory clearance to start clinical trials for FLT201, an experimental gene therapy for Gaucher disease Type 1. Gaucher disease is a hereditary disorder that can affect multiple organs. In Q3 2022, Freeline (FRLN) expects to report early data from the first cohort of its Phase 1/2 dose-finding trial of FLT201.

For further details see:

Freeline Therapeutics spikes as Syncona discloses stake
Stock Information
Company Name: Freeline Therapeutics Holdings plc
Stock Symbol: FRLN
Market: NASDAQ
Website: freeline.life
Menu
FRLN FRLN Quote FRLN Short FRLN News FRLN Articles FRLN Message Board
Get FRLN Alerts

News, Short Squeeze, Breakout and More Instantly...